TEAM

Partners

АВ.jpg

ALEXEY VINOGRADOV

Managing Partner

CEO

In life sciences – since 1995;

PhD in biochemistry – 2000;

In venture biotech – since 2010:

  • Bioprocess capital;

  • Inbio ventures;

  • Pharmstandard ventures;

  • Unicorn capital;

 

2013-2019 – member of the Board of Director at six US biotech and medtech companies:

  • Allena pharmaceuticals (went public on NASDAQ);

  • Aquinox (went public on NASDAQ);

  • Avelas biosciences;

  • Argos therapeutics (went public on NASDAQ);

  • Protagonist (went public on NASDAQ);

  • Tear Solutions;

 

https://www.linkedin.com/in/alexey-vinogradov-4b03645/

мг.jpg

MAXIM GORBACHEV

Managing Partner

 

Graduated in IT and applied math – 1997;

Graduated in financials – 2000;

MBA – since 2009;

In venture investments – since 2013:

  • RMI Partners;

  • Unicorn capital;

 

Since 2013 – member of the Board of Directors at:

  • Botkin AI;

  • UNIM;

  • Miramar Labs (IPO on NASDAQ, M&A);

  • Neothetics (IPO on NASDAQ, M&A);

  • Celtaxsys;

  • Binx health;

  • Vital healthcare;

  • Biotechware;

https://www.linkedin.com/in/maximgorbachev/

ПД.jpg

PETR DENISOV

Managing Partner

MD since 1996 (cum laude);

PhD in physiology – 1999;

Clinical CRO – since 2006:

  • Evidence;

  • Worldwide Clinical Trials;

  • Synergy Research Group;

 

In venture biotech – since 2014:

  • Inbio ventures;

  • Pharmstandard ventures;

  • Unicorn capital;

 

2016-2019 – member of the Board of Directors at US biotech and medtech companies:

  • Transmedics (went public on NASDAQ);

  • EnGene;

https://www.linkedin.com/in/petr-denisov-21ab318/